<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948726</url>
  </required_header>
  <id_info>
    <org_study_id>ARO 2013-04</org_study_id>
    <nct_id>NCT01948726</nct_id>
  </id_info>
  <brief_title>Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer</brief_title>
  <official_title>Multicenter Phase-II-Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypofractionation with simultaneous integrated boost has been investigated in a few trials
      and appears to be safe and feasible with less lung toxicity in smaller studies.

      Investigators initiated this multicenter phase II prospective trial to analyse acute toxicity
      of hypofractionation with simultaneous integrated boost in patients with early breast cancer
      under the hypothesis that the ratio of patients with acute radiogenic toxicity Grad II
      according NCI-CTCAE amounts maximum 20%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypofractionated radiotherapy of the breast 16 × 2.50 Gy with simultaneous integrated boost
      to the tumor bed (total dose within the boost volume 16 × 3.00 Gy).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Acute skin radiogenic toxicity grade II or higher according to NCI-CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>22-29 days (16 fractions)</time_frame>
    <description>Dose constraints Dmedian lung &lt; 10 Gy; Dmedian heart &lt; 5 Gy, Dmax ≤ 40 Gy; Dmedian anterior branch of the left coronary artery (LAD, RIVA) &lt; 15 Gy, Dmax ≤ 40 Gy; Dmedian contralateral breast &lt; 3 Gy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>All dimensions of NCI-CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>EORTC QLQ-C30, -BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>ECOG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Skin toxicity (Cosmetic results)</measure>
    <time_frame>0 to 6 months</time_frame>
    <description>NCI-CTCAE</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Breast Cancer After Breast Conserving Surgery Indicating Postoperative Radiotherapy With Boost</condition>
  <arm_group>
    <arm_group_label>Hypofractionation with SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation with simultaneous integrated boost</intervention_name>
    <arm_group_label>Hypofractionation with SIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed breast cancer operated by breast conserving surgery with
             clear margins

          -  Indication to adjuvant radiotherapy including boost radiotherapy

          -  Clearly identified primary tumor region preferably by radiopaque clips

          -  Primary wound healing after breast conserving therapy without signs of infection

          -  Pre- and/or postoperative chemotherapy and endocrine therapy were permitted when
             indicated

          -  Written informed consent

        Exclusion Criteria:

          -  Patients operated by mastectomy

          -  No indication for boost radiation

          -  Resection margins positive for disease or insufficient identification of the boost
             volume

          -  Indication for radiotherapy of the regional lymph nodes

          -  History of prior breast or thoracic radiotherapy

          -  Extended postoperative seroma at the beginning of radiotherapy

          -  Psychiatric disorders or psychological disabilities thought to adversely affect
             treatment compliance

          -  Pregnant or lactating patients and woman of child bearing potential, who lacked
             effective contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dunst, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Schleswig-Holstein (UKSH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité University Medical Center Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Buchholz</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum des Landkreises Deggendorf Mammazentrum</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie am Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologischer Schwerpunkt (OSP) Goeppingen</name>
      <address>
        <city>Goeppingen</city>
        <zip>73006</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlenzentrum Hamburg Nord</name>
      <address>
        <city>Hamburg</city>
        <zip>22419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiologie and Radioonkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein (UKSH), Department of Radiotherapy, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein (UKSH), Department of Radiotherapy, Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGZ Luebeck im Hochschulstadtteil</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Lueneburg</name>
      <address>
        <city>Lueneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz, Department of Radiotherapy</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rechts der Isar Department of Radiotherapy Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiology Pinneberg</name>
      <address>
        <city>Pinneberg</city>
        <zip>25421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Genthin-Stendal</name>
      <address>
        <city>Stendal</city>
        <zip>39576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Klinikum Straubing GmbH</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun-Klinikum Zwickau</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Juergen Dunst, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Juergen Dunst</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Hypofractionation</keyword>
  <keyword>Simultaneous integrated boost</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

